5-氯-4-甲氧基噻吩-3-羧酸 | 133659-14-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 5-氯-4-甲氧基噻吩-3-羧酸
• 中文别名: 2-氯-3-甲氧基噻吩-4-羧酸
• 英文名称: 5-chloro-4-methoxythiophene-3-carboxylic acid
• 英文别名: 2-chloro-3-methoxy-thiophene-4-carboxylic acid
• CAS: 133659-14-0
• 化学式: C₆H₅ClO₃S
• mdl: MFCD00067999
• 分子量: 192.623
• InChiKey: CEOFOUVVEMMYDW-UHFFFAOYSA-N

物化性质

• 熔点：
  140 °C
• 沸点：
  309.6±37.0 °C(Predicted)
• 密度：
  1.511±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  74.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 安全说明：
  S26,S37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  -20°C

SDS

Name:	5-Chloro-4-methoxythiophene-3-carboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS:	133659-14-0

Section 1 - Chemical Product MSDS Name:5-Chloro-4-methoxythiophene-3-carboxylic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
133659-14-0	5-Chloro-4-methoxythiophene-3-carboxyl	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 133659-14-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H5ClO3S
Molecular Weight: 193

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 133659-14-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Chloro-4-methoxythiophene-3-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 133659-14-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 133659-14-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 133659-14-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氯-4-甲氧基噻吩-3-羧酸 在 氯化铵 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以72%的产率得到5-chloro-4-methoxythiophene-3-carboxamide
  参考文献：
  名称：

  靶向ALK2：一种开放的科学方法，用于开发治疗弥漫性内源性庞廷胶质瘤的疗法。

  摘要：

  弥漫性桥脑神经胶质瘤是一种侵袭性小儿癌症，尚无有效的化疗药物。对这种疾病的基因组格局的分析已导致将丝氨酸/苏氨酸激酶ALK2鉴定为治疗干预的潜在靶标。在这项工作中，我们采用开放式科学方法开发了一系列有效的I型ALK2抑制剂，这些抑制剂可口服生物利用并具有脑渗透性。最初的努力导致发现了M4K2009，它是先前报道的ALK2抑制剂LDN-214117的类似物。尽管相对于TGF-βR1受体ALK5对ALK2具有高度选择性，但M4K2009对hERG钾通道也具有中等活性。改变三甲氧基苯基部分的取代基产生等价的苯甲酰胺类似物M4K2149，其对离子通道的脱靶亲和力降低。进一步的修饰产生了2-氟-6-甲氧基苯甲酰胺衍生物（26a-c），其具有对ALK2的高抑制活性，优异的选择性和优异的药代动力学特征。

  DOI：

  10.1021/acs.jmedchem.0c00395
• 作为产物：
  描述：

  4-甲氧基噻吩-3-羧酸 在 磺酰氯 作用下， 以 氯仿 为溶剂， 生成 5-氯-4-甲氧基噻吩-3-羧酸
  参考文献：
  名称：

  Organic compounds and their use as pharmaceuticals

  摘要：

  化学式为##STR1##的药物化合物，其中R.sup.1，R.sup.2和R.sup.3独立地是氢，羟基，卤素，硝基，氨基，C.sub.2-5酰胺基，C.sub.1-4烷基，--CHO，--CH.sub.2 OH，--CH.sub.2 OC.sub.1-4烷基，--COOH，--COC.sub.1-3烷基，--CH(OH)C.sub.1-3烷基，C.sub.1-4烷氧基，C.sub.2-4烯基氧基，C.sub.1-4烷基硫基，C.sub.1-4烷基磺酰基，C.sub.1-4烷基磺基，N-取代的杂环基，可选择取代的苯基，可选择取代的苯基硫基，可选择取代的苯基磺酰基，可选择取代的苯基磺胺基，或者R.sup.1和R.sup.2共同形成一个C.sub.3-5烷基桥；前提是R.sup.2和R.sup.3中至少有一个是C.sub.1-4烷氧基或C.sub.2-4烯基氧基；X为(i)--(CH.sub.2).sub.n N(R.sup.4).sub.2，其中每个R.sup.4独立地是C.sub.1-4烷基，C.sub.2-4烯基或可选择取代的C.sub.6 H.sub.5 CH.sub.2 --，n为1, 2或3，或者(ii)一个含有一个或两个氮原子的5-到8-成员的脂环基，直接连接到酰胺氮或通过一个C.sub.1-3烷基链连接；以及其盐和酯。

  公开号：

  US05015656A1

文献信息

• Chemical compounds
  申请人：——

  公开号：US20030187020A1

  公开（公告）日：2003-10-02

  Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.

  本文提供了具有胰蛋白酶抑制活性的新颖和有用化合物，包括含有这些化合物的药物组合物，以及治疗患有可以通过给予胰蛋白酶抑制剂（例如哮喘和炎症性疾病等）而得到改善的疾病、疾病或紊乱的方法。
• NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS
  申请人：Leonardi Amedeo

  公开号：US20090042841A1

  公开（公告）日：2009-02-12

  This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).

  本发明涉及一种新型杂环化合物，其具有选择性亲和力，适用于代谢型受体mGlu5亚型，以及该类化合物的制药组合物及其在治疗下尿路障碍（例如下尿路神经肌肉功能障碍）、偏头痛和胃食管反流病（GERD）方面的用途。
• [EN] 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS<br/>[FR] DERIVES DE 1-(2H-PYRAZOL-3-YL)-3-{4-`1-(BENZOYL)-PIPERIDIN-4-YLMETHYL!-PHENYL}-UREE ET COMPOSES ASSOCIES UTILISES COMME INHIBITEURS DE LA KINASE P38 ET/OU COMME INHIBITEURS DU FACTEUR DE NECROSE TUMORALE (TNF) DANS LE TRAITEMENT DES INFLAMMATIONS
  申请人：AVENTIS PHARMA INC

  公开号：WO2004100946A1

  公开（公告）日：2004-11-25

  The present invention provides compounds of Formula (I) Wherein ( ) is an optional ethylene bridge; R1 is alkyl, cycloalkyl, aryl or aryl substituted with one or more substituents selected from alkyl, alkoxy and amino, or R1 is pyridyl or pyridyl substituted with one or more substituents selected from alkyl, alkoxy and amino; R2 is optionally substituted alkyl, alkoxyalkyl, optionally substituted cycloalkylalkyl, arylalkyl, or R2 is arylalkyl substituted with one or more substituents selected from alkyl, alkoxy; X is -C(O)-, -C(O)-CH2-, -S(O)2-, or NH-C(O)- ; and A is optionally substituted alkyl or other substituents as defined in claim 1. Pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF), such as asthma or joint inflammation.

  本发明提供了Formula (I)的化合物，其中( )是可选的乙烯桥；R1是烷基、环烷基、芳基或芳基，其上取代基可为烷基、烷氧基和氨基中的一种或多种，或者R1是吡啶基或吡啶基，其上取代基可为烷基、烷氧基和氨基中的一种或多种；R2是可选取代的烷基、烷氧基烷基、可选取代的环烷基烷基、芳基烷基，或者R2是芳基烷基，其上取代基可为烷基、烷氧基中的一种或多种；X是-C(O)-、-C(O)-CH2-、-S(O)2-或NH-C(O)-；A是可选取代的烷基或其他在权利要求1中定义的取代基。包括这些化合物的药物组合物、其制备以及在治疗能够通过抑制p38激酶和/或肿瘤坏死因子(TNF)调节的疾病状态中的药用，如哮喘或关节炎。
• Substituted Cyclohexylmethyl Compounds
  申请人：OBERBOERSCH Stefan

  公开号：US20090286833A1

  公开（公告）日：2009-11-19

  Novel cyclohexylmethyl compounds corresponding to formula I wherein R 1 , R 2 , R 3 , R 4 and R 5 , have the meanings given in the description. Pharmaceutical formulations containing these compounds, as well as a processes for preparing these compounds and related methods of treatment are also provided.

  新型环己基甲基化合物对应于式I，其中R1、R2、R3、R4和R5在描述中给出了它们的含义。还提供了含有这些化合物的药物配方，以及制备这些化合物的过程和相关治疗方法。
• [EN] HETEROARYL-SUBSTITUTED 2-PYRIDINYLMETHYLAMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-PYRIDINYLMÉTHYLAMINE SUBSTITUÉS PAR HÉTÉROARYLE
  申请人：UNIV FRIEDRICH ALEXANDER ER

  公开号：WO2009060030A1

  公开（公告）日：2009-05-14

  The present disclosure relates to compounds having the general formula (I) wherein Q represents a five membered heteroaryl group. The compoungs are selective 5-HT1 a modulators and are useful for treating several diseases.

  本公开涉及具有通式（I）的化合物，其中Q代表五元杂环芳基基团。这些化合物是选择性5-HT1a调节剂，可用于治疗多种疾病。